PUTRAJAYA: Malaysia’s Covid-19 cases remain above the 2,000 mark, with more than half of the infections recorded in Selangor and Sarawak.
In his daily Covid-19 updates, Health director-general Tan Sri Dr Noor Hisham said there were 2,847 new cases in the country, bringing the cumulative total to 387,535.
“Selangor recorded the highest daily figure with 748 cases or 26.3% of the country’s cases.
“At least 80.5% of the cases in the state were uncovered from clusters and contact tracing activities.
“This is followed by Sarawak with 717 cases or 25.2%, and Kelantan with 476 cases (16.7%), ” said Dr Noor Hisham.
Other places recording three digits in their daily figure were Kuala Lumpur (302), Johor (130 new cases) and Negri Sembilan (105)
Eight more people succumbed to Covid-19, bringing the country’s Covid-19 death toll to 1,415.
“Kelantan, Sabah, Sarawak and Kuala Lumpur have two deaths each.
“All but one are Malaysian citizens, ” said Dr Noor Hisham.
Three deaths – one each at Hospital Tawau, Hospital Machang and the Duchess of Kent Hospital in Sandakan – were classified as “dead on arrival”.
Currently, there are 260 patients under intensive care with 125 requiring ventilator support.
Active cases have now gone up to 22,512.
Another 2,341 patients were discharged from treatment yesterday, taking the total recoveries to 363,608 (93.8%).
The ministry also identified eight new clusters in the country, of which five were related to the education sector.
There were also two new clusters which were classified as community outbreaks, while one is a workplace cluster.
Meanwhile, Dr Noor Hisham said Sinovac’s “CoronaVac” vaccine which is “filled-and-finished” locally by Pharmaniaga LifeScience Sdn Bhd (PLS) received conditional approval from the Drug Control Authority yesterday.
Fill and finish is the process of filling vials with vaccines and finishing the process of packaging the medicine for distribution.
Before this, Malaysia had given conditional approval to the finished doses of the CoronaVac vaccine produced by Sinovac in China.
Dr Noor Hisham said the deal for PLS to carry out the fill-and-finish process of the CoronaVac vaccine is an achievement for Malaysia, which has been relying on imported vaccine and plasma products.
“Hopefully, this development can spur the growth of the local pharmaceutical industry in the production of such products, ” he said.
In January, PLS signed an agreement with Sinovac to purchase 14 million doses of Covid-19 vaccines, which will then be “filled and finished” at its facilities in Puchong, Selangor.